fashion -WSS

fashion

author：entertainment 2025-08-12 11:30:02 - browse：318

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Stephen Quake on the Chan Zuckerberg quest to conquer disease

hotspot

WSS

Teladoc has a new CEO, but challenges remain the same

STAT Virtual Event: ASCO Recap, Live!

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

The a glaring gap in research on serious mental illness and primary care

Coercive sterilizations revealed by STAT prompt outrage

Group behind ProMed defends move to subscription

focus

fashion

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Physicians aren't 'burning out.' They're suffering from moral injury

As demand for Covid shots wanes, Moderna seeks its next success

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Bright Health sells Medicare Advantage business to Molina

Statins may not be needed by millions of people, study suggests

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

My daughter's legacy lives on through her writing, phage therapy

Guidelines to prevent youth baseball injuries need more muscle

Medicare slashes safety net hospital payments by nearly $1 billion

focus

Curing rare childhood diseases will falter unless Congress steps up

H.R. 3 is the wrong path to lower drug costs

Curing rare childhood diseases will falter unless Congress steps up

Curing rare childhood diseases will falter unless Congress steps up

Readers discuss the intersection of pregnancy and addiction

Curing rare childhood diseases will falter unless Congress steps up

hotspot

hotspot

hotspot

hotspot